FDA cites Taiwan API plant for its filthy, smelly rooms, uncleaned equipment

FDA sign

A Taiwanese API maker is in hot water with the FDA, which has issued it a warning letter after an inspection in which investigators found a foul-smelling, filthy plant with insects and layers of unidentified material on the floors of rooms that had never been cleaned.

The warning letter was issued Sept. 15 to Taoyuan City-based Cheng Fong Chemical and posted today after an inspection in April.  

The letter says said that among other problems, the plant had not been adequately investigating customer complaints of black particles in APIs. In fact, the report says that after getting a complaint, Cheng Fong investigated another batch, where it also found black particles, but then didn’t bother to find the root cause of particulate for either batch.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The company said the source was probably from equipment that was in poor condition. The investigators did find equipment that was corroded, dirty, pitted on the product surface of the equipment and leaking on and around the equipment. But it said the company had not determined for sure that was the cause.

Investigators also found cold rooms storing raw materials and intermediates used to make APIs that had foul odors and which officials acknowledged “had never been cleaned.”

The FDA told the company that it needs to resolve its customer complaints by figuring out the source of the black particulate, and update and assess its maintenance program.

The FDA is putting more resources into inspecting Asian manufacturers and some need big improvements. Earlier this year, the FDA issued a warning letter to Taiwanese API maker KO DA Pharmaceutical after finding the plant had no written procedures for production and process controls or for the preparation of master production and control records to assure batch uniformity. Rather than fix the problems, KO DA told the FDA it instead would simply quit exporting to the U.S. the one product it was selling there.

- read the warning letter

Related Articles:
Taiwanese API maker abandons U.S. market rather than concede to FDA
China's Zhejiang Hisoar slapped with FDA warning
Chinese API maker spanked in warning letter
FDA warns China's Concept Products: test your products

Read more on

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.